...
首页> 外文期刊>Stem cells and development >Bovine Posterior Limbus: An Evaluation of an Alternative Source for Corneal Endothelial and Trabecular Meshwork Stem/Progenitor Cells
【24h】

Bovine Posterior Limbus: An Evaluation of an Alternative Source for Corneal Endothelial and Trabecular Meshwork Stem/Progenitor Cells

机译:牛后唇:角膜内皮和小梁网干/祖细胞的替代来源的评估。

获取原文
获取原文并翻译 | 示例

摘要

A growing body of evidence has revealed that stem-like cells in the posterior limbus of the eye between the corneal endothelium (CE) and trabecular meshwork (TM) may be able to rejuvenate these tissues in disease. However, these cells have not been clearly defined and we have named them PET cells (progenitor cells of the endothelium and trabeculum). A good and inexpensive animal model for PET cells is lacking, so we investigated bovine eyes as an effective large tissue source. We showed the presence of stem/progenitor cells in the bovine CE, transition zone, and TM in situ. Floating spheres cultured from the CE and TM showed similar stem cell marker expression patterns. Both the CE and TM spheres were bipotent and highly proliferative, but with limited secondary sphere-forming capability. They were highly prone to differentiate back into the cell type of their tissue of origin. It is speculated that the PET cells become more tissue-specific as they migrate away from their niche. Here, we showed that PET cells are present in the posterior limbus of bovine eyes and that they can be successfully cultured and expanded. PET cells represent an attractive target for developing new treatments to regenerate both the CE and TM, thereby reducing the requirement for donor tissue for corneal transplant and invasive treatments for glaucomatous patients.
机译:越来越多的证据表明,在角膜内皮(CE)和小梁网(TM)之间的眼后缘的干样细胞可能能够使这些组织恢复活力。但是,这些细胞尚未明确定义,我们将其命名为PET细胞(内皮和小梁的祖细胞)。缺乏用于PET细胞的良好且便宜的动物模型,因此我们研究了牛眼作为有效的大型组织来源。我们显示了牛CE,过渡区和TM原位存在干/祖细胞。从CE和TM培养的浮球显示出相似的干细胞标记物表达模式。 CE和TM球都是双能且高度增殖的,但次级球形成能力有限。它们极易分化回其起源组织的细胞类型。据推测,随着PET细胞从其利基迁移出来,它们变得更具组织特异性。在这里,我们表明,PET细胞存在于牛眼后缘,并且可以成功地培养和扩增。 PET细胞是开发可再生CE和TM的新疗法的有吸引力的靶标,从而减少了角膜移植对供体组织的需求以及对青光眼患者的侵入性治疗。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号